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a  b  s  t  r  a  c  t
Posttranslational  modiﬁcations  of  proteins  are  important  regulatory  processes  endowing  the proteins
functional  complexity.  Over  the  last  decade,  numerous  studies  have  shed  light  on the roles of  palmitoyla-
tion,  one  of the  most  common  lipid  modiﬁcations,  in  various  aspects  of  neuronal  functions.  Major  players
regulating  palmitoylation  are  the  enzymes  that  mediate  palmitoylation  and  depalmitoylation  which  are
palmitoyl  acyltransferases  (PATs)  and  protein  thioesterases,  respectively.  In  this  review, we  will  provide
and  discuss  current  understandings  on  palmitoyation/depalmitoylation  control  mediated  by  PATs  and/oreywords:
osttranslational modiﬁcations
almitoylation
almitoyl acyltransferases
rotein thioesterases
lzheimer’s disease
protein thioesterases  for neuronal  functions  in  general  and also  for  Alzheimer’s  disease  in particular,  and
other neurodegenerative  diseases  such  as Huntington’s  disease,  schizophrenia  and intellectual  disability.
© 2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).eurodegenerative diseases
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respectively, were identiﬁed and characterized as the ER target-
ing signals. The fact that the dilysine signals are sufﬁcient for their
ER localization was revealed by motif swapping experiment with aReferences  . .  . . . .  . . .  .  . . . .  . . . .  . . . .  .  . . .  .  . .  .  . . .  . . . .  . . .  . . . . .  . . .  .  . . .  . . .  . . . .  . 
. Introduction
Protein posttranslational modiﬁcations (PTMs), including phos-
horylation, ubiquitination, sumoylation, nitrosylation, glycosyla-
ion, and lipidation are the key regulatory steps that contribute
o the functional complexity of proteins. Of these PTMs, lipidation
ncreases the hydrophobicity of proteins, which make the proteins
o be associated with membranes of intracellular organelles such
s the endoplasmic reticulum (ER), Golgi apparatus, endosomes,
itochondria and plasma membrane. Myristoylation, prenylation
nd palmitoylation are the most common lipid modiﬁcations and
lay roles in protein trafﬁcking, targeting, and function [1–6]. Of
hese three lipid modiﬁcations, only palmitoylation is reversible
7,8] that allows more dynamic regulation of protein function in
arious aspects of cellular signaling. Intriguingly, palmitoylation is
ost often observed in neuronal cells and it indeed plays critical
oles in neuronal function [9].
Protein palmitoylation is occurred by the covalent attachment
f a 16-carbon palmitate to internal cysteine residues of pro-
eins via thioesther bonds. This process is catalyzed by a family
f palmitoyl acyltransferases (PATs) (Fig. 1), containing a con-
erved Asp-His-His-Cys (DHHC) motif [9–12], and many of them
ave been reported to be expressed in neurons [13,14]. Roles of
almitoylation in neuronal function have begun to receive atten-
ion since a synaptosomal-associated protein 25 (SNAP-25) was
eported as a palmitoylated synaptic protein [15–19]. Since then,
here have been extensive studies on the roles of palmitoylation
n protein targeting and many other aspects of neuronal function,
ncluding intracellular trafﬁcking pathway mechanisms underly-
ng synaptic transmission and plasticity [20–28]. Disruption of
rotein palmitoylation has been implicated in pathogenesis of
eurodegenerative diseases, including Alzheimer’s disease (AD),
untington’s disease (HD), schizophrenia and intellectual disabil-
ty (ID) [9,29,30]. DHHC proteins were selectively paired with
heir speciﬁc substrates, and the palmitoylation through DHHC-
ubstrate interactions is closely involved in their function. In this
eview, we provide the current understandings on the DHHC PAT
roteins, especially whose respective substrate pairs were iden-
iﬁed, the functions based on the DHHC-substrate pair, and the
oles of palmitoylation and depalmitoylation in neurodegenerative
iseases with an intense focus on the AD. .  . .  . . . .  . . .  . . . . .  .  . . . . .  . .  .  .  . . .  . . .  . . . . . . .  .  . . .  .  . . . .  .  .  . . . . .  . . . . . . .  .  .  .  . . .  .  . .  . . . .  .  145
2. Palmitoylation
2.1. Subcellular localization of DHHC PAT proteins
There are at least 23 mammalian DHHC proteins that exhibit
speciﬁc localizations in intracellular compartments. The intracel-
lular colocalization analysis of all mammalian DHHCs exogenously
expressed in in vitro with endogenous intracellular organelle
marker proteins revealed that the majority of DHHC proteins local-
ize to the ER and Golgi, and a small number of DHHC proteins
localize to post-Golgi membranes, including endosomes and synap-
tic vesicles [31,32] (Table 1). Because most of current knowledge
on the subcellular localization of DHHC proteins is based on co-
expression studies, it will be important to obtain more reliable
ﬁndings with endogenous DHHC proteins. It will also need to
investigate a differential intracellular distribution of DHHC pro-
teins in different cell types. Indeed, DHHC2 that was  reported as
a Golgi-residency in HEK293T cells [31] was shown to localize on
dendritic vesicles in cultured hippocampal neurons [23] and the
plasma membrane in PC12 cells [33]. DHHC21 also displayed dif-
ferent localization patterns in various cell types; it was  located on
the plasma membrane in HEK293 T cells [31] and to the Golgi in
primary keratinocytes [34]. In COS-7 cells, DHHC21 was  found to
localize primarily to the Golgi, while some were still observed on
the plasma membrane [35]. DHHC5 was mainly located to den-
dritic shaft in cultured hippocampal neurons [28] and to the plasma
membrane in HEK293 T cells [31]. DHHC8 was  largely localized to
dendrites, mainly to the synaptic region in spines [28] or to den-
dritic vesicles in cultured hippocampal neurons [36]. In addition,
several among the 23 DHHCs exhibited different localizations in
cultured hippocampal neurons (unpublished data in the Park labo-
ratory) from the ones reported in HEK293T cells [31].
There has been no report on how the DHHC proteins arrive at
their respective intracellular localizations till the study on 2011,
which showed the ER sorting signals for DHHC4 and DHHC6 [37].
The KXX and KKXX motif (last X indicates the last amino acid
of the proteins) at the extreme C-termini of DHHC4 and DHHC6,Golgi-resident DHHC3 protein [37].
E. Cho, M.  Park / Pharmacological Research 111 (2016) 133–151 135
Covalent  att achment 
via thioes ter bondPAT (DH HC en zyme)
APT, PPT
SH
CH3
CoA
S
C
O
Cys Cys
CH3S
C
O
Palmitoyl-CoA Target protein Palmitoylated protein
Palmitoylation
Depalmitoylation
Fig. 1. Palmitoylation-depalmitoylation cycle.
Palmitoylation is achieved by attaching a 16 carbon-containing saturated fatty acid palmitate to speciﬁc cysteine residues of target proteins via thioester bonds, which is cat-
alyzed  by palmitoylacyltransferases (PATs), also known as DHHC enzymes. Reversibly, depalmitoylation is mediated by releasing the palmitate group from the palmitoylated
proteins, which is catalyzed by acyl protein thioesterases (APT) or palmitoyl protein thioesterase (PPT).
Table 1
Subcellular localization of DHHC PAT proteins.
*zDHHC Alternative names Intracellular localization References
1 DHHC1 ER [31]
EE [69]
2 DHHC2 ER/Golgi [31]
Dendritic vesicles in neuron [23]
PM,  recycling endosome [33,262]
3 DHHC3, GODZ, Erf2 Golgi [24,31,72,147] (in neurons)
4  DHHC4 ER [37]
Golgi [31]
5 DHHC5 PM [31]
Endosomes in dendritic shafts [28]
6 DHHC6 ER [31,37]
7 DHHC7 Golgi [31,147] (in neurons)
8  DHHC8 Golgi [31,36]
Dendritic vesicles [36]
Spines in neuronal cells [28]
9 DHHC9 ER/Golgi [31,85]
11 DHHC10 ER [31]
EE [69]
12 DHHC12, AID ER/Golgi [31]
13 DHHC22, HIP14L ER/Golgi [31,263]
14 DHHC14 ER [31]
15 DHHC15 Golgi [31,33,147] (in neurons)
16  DHHC16 ER [264]
17 DHHC17,
HIP14,
Akr1p
Golgi [31,40,41,263]
Intracellular vesicles [40]
Presynaptic terminals [265]
18 DHHC18 Golgi [31]
19 DHHC19 ER [31]
20 DHHC20 PM [31]
21 DHHC21 PM [31,35]
Golgi [34,35]
22 Unknown
23  DHHC11,
NIDD
ER [31]
PM (synaptic) [266]
ER 
E
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h
t
t
a
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t
d24 DHHC13 
R, endoplasmic reticulum; EE, early endosome; PM,  plasma membrane.
* Used in the text.
.2. Substrate speciﬁcity
Such subcellular localizations of DHHC proteins have been con-
idered as a determinant of substrate speciﬁcity [9,23]. In contrast,
owever, there was a report that palmitoylation is restricted only
o the Glogi [38]. Deﬁning the localization of individual DHHC pro-
eins is still under construction because the localization would be
ffected by the cell types and experimental conditions [29,39] and
lso because the functional intracellular localization of each DHHC
rotein depends on its substrates.
The fact that DHHC proteins exhibit substrate speciﬁcity despite
he commonly shared active region, the DHHC − cysteine rich
omain (CRD) has implied the possibility of existence of reg-[31]
ulatory domains outside of the common active region. Indeed,
ankyrin repeats of DHHC17 [40,41], Src homology 3 (SH3) domain
of DHHC6 [42], and PDZ-binding motif of DHHC3, DHHC5, and
DHHC8 [9,28,43,44] were identiﬁed as the regulatory regions out-
side DHHC − CDR to affect the recruitment of speciﬁc substrates and
their catalytic activity. There is another report showing that regions
distinct from the palmitoylated cysteine residues are important for
the speciﬁc substrate recognition by DHHC proteins. The yeast vac-
uolar protein 8 (Vac8) contains 11 armadillo repeats which are
involved in protein-protein interactions [45,46] and is palmitoy-
lated by DHHC Pfa3 [47]. The 11th armadillo repeat of Vac8 was
revealed as an important region for Pfa3 recognition [48].
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Palmitoylation occurs at the various cysteine residues located
t diverse region of various substrates [49]. For instance, palmitoy-
ated cysteines have been found in the N-terminal region of the
ostsynaptic density 95 (PSD-95), the growth-associated protein
GAP-43) and G, the internal region of SNAP-25, the cysteine string
rotein (CSP), and glutamate decarboxylase 65 (GAD65), the C-
erminal region of H-Ras, N-Ras and Rho B, and the juxtamembrane
r transmembrane region of various transmembrane proteins [9].
he consensus sequences for other lipidations such as myristoy-
ation and isoprenylation were already identiﬁed as glycine in
he N-terminal MGXXXS/T (M,  Met; G, Gly; S, Ser; T, Thr; X, any
mino acid) for myristoylation and cysteine in the C-terminal CAAX
otif (C, Cys; A, an aliphatic amino acid; X, any amino acid) for
soprenylation [49]. Regarding the consensus sequence for palmi-
oylation, a very recent report identiﬁed a novel sequence motif
hat is recognized by the ankyrin repeat domain of DHHC17 and
HHC13, which is the ﬁrst demonstration of a motif as consensus
equences of substrates recognized by ankyrin repeat-containing
HHCs [50]. A number of DHHC17 substrates and DHHC17- and
HHC13-interacting palmitoylated proteins, including SNAP-25b,
NAP-23, CSP, huntingtin, cytoplasmic linker protein 3 (CLIP3),
nd microtubule associated protein 6 (MAP6) contain a XXQP
, an aliphatic amino acid; , a C-  branched amino acid Val, Ile,
r Thr; X, any amino acid; Q, Gln; P, Pro) motif. The consensus
equence was recognized by DHHC17 and DHHC13 via the ankyrin
epeats domain in their cytosolic N-terminus [50]. The consen-
us sequences for the recognition by and catalytic activity of most
HHC proteins will need to be identiﬁed.
. Palmitoyl acyltransferases (PATs)
.1. Structure of DHHC PAT proteins
Most PATs are predicted to have four transmembrane domains
TMDs) (Fig. 2). Both N- and C- termini and DHHC − CRD of PATs are
aced toward the cytoplasmic side. The DHHC − CRD, consisting of
1 amino acids is located in the cytoplasmic loop between the sec-
nd and third TMDs, while it is more proximal to the third TMD. A
maller subset of the DHHCs such as DHHC13 and DHHC17 have
ix predicted TMDs with ankyrin repeats-containing N-terminal
egion and a DHHC-CRD located in the cytoplasmic loop between
he fourth and ﬁfth TMD  [51] (Fig. 2). Most DHHCs also have
dditional conserved domains, a DPG (Asp-Pro-Gly) and a TTXE
Thr-Thr-X-Glu) motif, which are found to lie on the cytoplasmic
ide adjacent to the second and fourth TMDs (Fig. 2A–D) or fourth
nd sixth TMDs (Fig. 2E and F), respectively. The role of these motifs
n PAT activity needs to be addressed [52]. There is another motif,
he PaCCT (palmitoyltransferase conserved C-terminus) motif con-
aining 16 amino acids proximal to the C-terminus following the
orth TMD, and this motif was reported to be required for the func-
ion of yeast PATs, Swf1 and Pfa3 [53]. The DHHC − CRD is a zinc
nger domain which is similar to the C2H2 zinc ﬁnger motif [54]
nd is sufﬁcient to be considered as a candidate for zinc binding site.
ndeed, several DHHC proteins, including DHHC1, DHHC4, DHHC6,
HHC14, DHHC16, and DHHC22 are predicted to have zinc binding
apacity [32].
.2. Enzymatic activity of PATs
Although the PTM palmitoylation had been studied for far over
he three decades since it was ﬁrst described [55], the mechanism
n which molecules are involved had been unknown till 2002 when
he two yeast PATs were identiﬁed [56,57]. A yeast work reported
kr1 as a PAT for the yeast casein kinase 2 (Yck2) [57]. Mutations
ithin the DHHC − CRD of Akr1 eliminated the PAT activity, sug-esearch 111 (2016) 133–151
gesting that the DHHC − CRD is the catalytic core for PAT activity.
A yeast genetic screening with a palmitoylation-dependent Ras2
allele identiﬁed Erf2 which contains the DHHC motif as a PAT
for Ras2. Expression of Ras2 in an erf2 deletion strain reduced
the palmitoylation level of Ras2 [58]. In addition, mutations on
conserved residues within the DHHC-CRD of Erf2 abolished Ras
PAT activity of Erf2 [56,58]. Unlike Akr1, Erf2 required Erf4 as a
cofactor for its Ras PAT activity [56]. These studies indicated that
DHHC sequence is critical for the PAT activity of Akr1 and Erf2,
initially suggesting that DHHC family proteins are PATs. To date,
a number of DHHC family proteins have been predicted in various
species, including the yeast Saccharomyces cerevisiae (7 genes) [57],
Caenorhabditis elegans (15 genes) [59], the fruit ﬂy Drosophila (22
genes) [60], the mouse and human (23 genes) [9,32], and even the
plant Arabidopsis (24 genes) [61,62]. Among these DHHC proteins, 6
(Akr1, Erf2, Swf1, Pfa3, Pfa4 and Pfa5) in yeast [47,52,57,63–66], 20
(DHHC1 − 9, DHHC11 − 21) in mammals [25,42,67–69], and 2 (TIP1
and PAT10) in plants have already been conﬁrmed as PATs [70,71].
Other DHHCs need to be addressed for their catalytic activity as
PATs.
3.3. DHHC PAT − substrate pairs
In 2004, three groups of researchers for the ﬁrst time reported
on the mammalian DHHCs and their substrates [10,41,72] (Table 2).
DHHC3, also known as Golgi-speciﬁc DHHC zinc ﬁnger protein
(GODZ) [73] palmitoylates the 2 but not  or  subunit of
-aminobutyric acid (GABA) A (GABAA) receptors [72], and the
DHHC3-mediated palmitoylation of the 2 subunit affects the traf-
ﬁcking and targeting of postsynaptic GABAA receptors [72,74,75].
Besides the function of DHHC3/GODZ in the inhibitory synapses
through the palmitoylation of GABAA receptors and GAD65
[72,74–76], DHHC3/GODZ also displayed a catalytic activity
for the excitatory glutamate receptors, including -amino-3-
hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors [77]
and N-methyl-d-aspartate (NMDA) receptors [21]. The AMPA
receptors palmitoylated on the second TMD  at C585 in GluA1
and at C610 in GluA2 increased Golgi accumulation and reduced
surface expression of the receptors whereas the C-terminal palmi-
toylated AMPA receptors at C811 in GluA1 and at C836 in GluA2
were normally expressed on the surface and this C-terminal palmi-
toylation inhibited the AMPA receptor interaction with the 4.1 N
protein [77] that has previously been reported to stabilize the sur-
face expression of AMPA receptors [78] and thus promoted AMPA
receptor endocytosis [77]. NMDA receptor subunits GluN2A and
GluN2B have two distinct clusters of palmitoylation sites in their
C-terminal region. DHHC3/GODZ also palmitoylates the cysteine
cluster in the middle of C-terminus of GluN2A and GluN2B (C1214,
C1217, C1236, and C1239 in GluN2A; C1215, C1218, C1239, C1242,
and C1245 in GluN2B) [21]. Similar to the case of AMPA recep-
tors, DHHC3/GODZ-mediated palmitoylation of NMDA receptors
increased Golgi accumulation and reduced surface expression of
the receptors [21]. Given that DHHC3/GODZ plays a role in both
inhibitory and excitatory synapses, it is highly conceivable that
DHHC3/GODZ might be a crucial factor to regulate the excitation
and inhibition balance in the brain, whose disturbance could lead
to various neurological disorders.
PSD-95 is undoubtedly a major palmitoylated synaptic protein
in neuronal cells [79] and the signiﬁcance of PSD-95 palmitoy-
lation has been addressed in multiple studies [79–81]. DHHC2,
DHHC3/GODZ, DHHC7 and DHHC15 were identiﬁed as PATs for
PSD-95 [10]. Turnover of palmitoylation cycle of PSD-95 is rapid
[81], and its palmitoylation regulates the postsynaptic targeting
of PSD-95 in cultured hippocampal neurons [79,80]. Interestingly,
depalmitoylation of PSD-95 is required for the rapid endocytosis
of AMPA receptors [81], suggesting that DHHC2, DHHC3/GODZ,
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Fig. 2. Schematic illustration of structures of mammalian and yeast DHHC protein family.
(A  − B) DHHC proteins mostly have four transmembrane domains (TMD1 − 4), a conserved cysteine-rich domain-containing DHHC motif in the cytoplasmic loop proximal to
the  TMD3, and other conserved domains, DPG (Asp-Pro-Gly) motif immediately next to the C-terminus of TMD2 and TTxE (Thr-Thr-X-Glu) motif adjacent to the C-terminus
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wf  TMD4. Swf1 and pfa3, the yeast DHHCs, have the PaCCT (Palmitoyltransferase Con
HHC13 and DHHC17 have six TMDs and an N-terminal extension containing seve
he  N-terminal cytosolic region (D).
HHC7 or DHHC15 regulates AMPA receptor trafﬁcking and
MPA receptor-mediated synapse function via PSD-95 palmitoyla-
ion. Intriguingly, a synaptic activity blocker tetrodotoxin-induced
almitoylation of PSD-95 is mediated only by DHHC2 but not by
HHC3/GODZ. Following the blockade of synaptic activity, den-
ritically localized DHHC2 rapidly translocates to the postsynaptic
lasma membrane where DHHC2 induces palmitoylation of PSD-
5, synaptic accumulation of PSD-95 and synaptic recruitment of
MPA receptors [23]. Thus, it would be important to test whether
HHC2 is involved in an activity-dependent synaptic plasticity
uch as long-term potentiation (LTP) and long-term depression
LTD). Indeed, a recent work demonstrated that knockdown of
HHC2 failed to express the features of LTP such as AMPA receptor-
ediated synaptic potentiation and spine enlargement in cultured
ippocampal neurons, and it was also shown that palmitoylation
f protein A-kinase anchoring protein 79 (AKAP79) by DHHC2 is
ssential for the synaptic potentiation [82].
DHHC5 has been reported to interact with PDZ3 domain of PSD-
5 through its C-terminus [43]. In the study using mice homozygous
or a hypomorphic allele of the DHHC5 gene, which express DHHC5
t low levels, DHHC5 was highly enriched in PSD and the contex-
ual fear conditioning was markedly impaired [43]. These ﬁndings
uggested a role for DHHC5 in postsynaptic function and learn-
ng and memory. Indeed, a couple of studies have reported the
mportance of DHHC5 for postsynaptic trafﬁcking of AMPA recep-
ors and synaptic plasticity [28,83]. Glutamate receptor interacting
rotein 1b (GRIP1b) was identiﬁed as a neuronal substrate for
HHC5 and also for DHHC8 using yeast two-hybrid (Y2H) screen-
ng with DHHC8 C-terminal region containing PDZ motif as a
ait [28]. In cultured hippocampal neurons, DHHC5 and DHHC8
ere largely localized to dendrites, mainly to dendritic shafts andd C-Terminus) motif towards the C-terminus after TMD4 and TTxE motif (B). (C − D)
ryin repeats (C) while the yeast DHHCs Ark1 and Ark2 have six ankryin repeats at
synaptic region in the spine, respectively. Palmitoylated GRIP1b
by DHHC5 and DHHC8 was  targeted to dendritic endosomes and
accelerated activity-dependent AMPA receptor recycling [28]. In
addition, -catenin, an intracellular binding protein of cadherin
that functions as a synaptic adhesion molecule, was  found as a sub-
strate for DHHC5 and it was  transiently palmitoylated at last two
cysteines C960 and C961 in the C-terminus among 18 cysteine can-
didates following enhanced synaptic activity [83]. Palmitoylation of
-catenin increased its interaction with cadherin at synapses and
was required for activity-induced spine enlargement, AMPA recep-
tor insertion into the synaptic plasma membrane, and an increase
in miniature excitatory postsynaptic current (mEPSC) amplitude.
In mice, contextual fear conditioning increased palmitoylation of
-catenin and its associations with N-cadherin [83]. DHHC5 also
palmitoylated ﬂotillin-2 that is a lipid raft protein [84] and was
suggested to be important for development because the mice
homozygous for a hypomorphic allele of the DHHC5 gene had a
birth rate that was half the expected rate [43] (Table 3).
A mammalian orthologue of Akr1, DHHC17 [11] which was
identiﬁed as a huntingtin-interacting protein, HIP14 [40] exhib-
ited substrate speciﬁcity for SNAP-25, PSD-95, GAP-43, GAD65,
synaptotagmin I, and huntingtin, but not for paralemmin and
synaptotagmin VII [41]. Similar to PSD-95 palmitoylating DHHCs,
DHHC17/HIP14 is also involved in the palmitoylation-dependent
vesicular trafﬁcking and clustering of several palmitoylated pro-
teins [41].
There are a few DHHC proteins whose PAT activity has been
reported to require a cofactor [42,85,86] although the majority of
DHHC proteins appear to have a catalytic activity independently
without other protein cofactors [87]. Yeast Ras is palmitoylated
by a PAT Erf2 in a form of complex with Erf4 as a cofactor [56].
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Table  2
DHHC-substrate pairs and related neurodegenerative diseases.
*zDHHC Speciﬁc substrates References for substrates Related diseases References for diseases
1 Ncdn [69]
2 PSD-95; eNOS; CD9/CD151;
AKAP79;
[10,267]; [35]; [268]; [82];
NDE1/NDEL1; CKAP4; Gi2;
GAP-43;
[269]; [270];[271]; [10];
ABCA1; Lck; SNAP-25; PI4KII [272]; [87]; [33]; [273]
3 GABAAR2; PSD-95; GluA1/2;
eNOS;
[72]; [10]; [77]; [35];
GluN2A/2B; CaMKIGs
(CLICK-III); CSP;
[21]; [274]; [275];
NCAM140/180; GluN2A/2B;
GAP-43;
[276]; [21]; [10];
GAD65; NDE1/NDEL1; BACE1; [76];[269]; [151];
Gq, Gs, Gi2; SNAP-25/-23;
STREX;
[271]; [33]; [88];
Stathmin 2/SCG10; Ncdn;
PI4KII;  D2R
[147]; [69]; [273]; [277]
4 BACE1; D2R [151]; [277]
5 STREX; GRIP1b; ﬂotillin-2;
-catenin
[88]; [28]; [84]; [83]
6 Calnexin; IP3R [68]; [42]
7 PSD-95; eNOS; GABAAR2;
GAP-43; NCAM140/180; CSP;
NDE1/NDEL1;
[10]; [35]; [74]; [10];
[276]; [275]; [269];
Alzheimer’s disease [142]
BACE1; APP; Gq, Gs, Gi2; [151]; [142]; [271];
SNAP-25/-23; STREX; Sortillin; [33]; [88]; [278];
Stathmin 2/SCG10; PI4KII [147]; [273]
8 eNOS; PSD-95; Paralemmin-1,
GAD65;
[35]; [239]; [76]; Schizophrenia [36,237,239,240]
ABCA1; GRIP1b; PICK1; D2R; [272]; [28]; [187]; [277]; Bipolar disorder [36,236]
Cdc42, Rac1 [240]
9 H-Ras, N-Ras; STREX [85]; [88] X-linked intellectual disability [248,251–253]
11 Ncdn [69]
12 ABCA1; Gephyrin [272];[279] Alzheimer’s disease [139]
13 Huntingtin, GAD65; SNAP-25 [76],[229](huntingtin);
[230]
Huntington’s disease [229,230]
14 PI4KII [273]
15 PSD-95; CSP; SNAP-25b;
ABCA1;
[10]; [275]; [33]; [272]; X-linked intellectual
disability
[250]
GABAAR2; BACE1; [74]; [151];
CD151; CI-MPR, sortillin; [268]; [278];
Stathmin 2/SCG10; GAP-43;
PI4KII
[147]; [10];[273]
17 Lck; CSP; huntingtin, GAD65,
GluA1/2;
[10]; [275]; [41,76]; Huntington’s
disease
[40,41,224,226,227]
SNAP-25/-23; [41] (SNAP-25), [33];
Stathmin 2/SCG10; PSD-95,
GAP-43;
[147];[10];
GPM6A, SPRED1/3; CLIPR-59;
STREX
[232]; [280]; [88]
18 H-Ras, N-Ras; H-Ras, Lck [85]; [10]
19 R-Ras [281]
20 ABCA1; BACE1; -catenin [272]; [151]; [83]
;
3]
B
m
(
f
a
P
p
b
t
m
d
i
t
f
i21 Fyn, Lck, eNOS; eNOS; ABCA1; [34]; [35]; [272]
APP; Gi2; PI4KII [142]; [271]; [27
* Used in the text.
y a sequence homology search of yeast Erf2 − Erf4 complex, the
ammalian DHHC9 − Golgi complex associated protein of 16 kDa
GCP16) complex was uncovered to have a PAT activity speciﬁc
or H-Ras and N-Ras. GCP16 as a cofactor is required for DHHC9
utopalmitoylation and Ras palmitoylation [85]. Recently, another
AT DHHC6 has been shown to palmitoylate the Ca2+ channel
rotein, inositol-1,4,5-triphosphate receptor (IP3R) in the ER mem-
rane, and the selenoprotein K (Selk) whose expression is sensitive
o dietary selenium levels functions as a cofactor in the DHHC6-
ediated IP3 R palmitoylation as revealed by that Selk deﬁciency
ecreased palmitoylation and stability of the IP3 R [42,86]. Interest-
ngly, Selk contains an SH3 domain while DHHC6 is also predicted
o contain an SH3 domain. Thus, DHHC6/Selk complex could be
ormed through SH3/SH3 interaction for the DHHC6 enzyme activ-
ty [42], suggesting the SH3 domain as a regulatory domain inAlzheimer’s disease [142]
DHHC6/Selk-mediated palmitoylation. Calnexin that is a major ER
chaperone involved in glycoprotein folding was  reported to be
palmitoylated by DHHC6 with no requirement of other cofactors
[68]. It seems that requirement of cofactors for PAT activity is not
dependent on DHHC proteins rather it may  depend on the sub-
strates because STREX channel palmitoylation by DHHC9 [88] and
calnexin palmitoylation by DHHC6 [68] do not require any cofac-
tors for their PAT activity. More pairs of different DHHCs and their
substrates are summarized in Table 2.
4. Depalmitoylating enzymesIn contrast to the intensive studies on PATs, current understand-
ings on the depalmitoylating enzymes are relatively very limited
although they surely are the key players along with the PATs in the
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Table  3
Depalmitoylating enzymes, their substrates and related neurodegenerative diseases.
Enzyme Gene Substrates References for substrates Associated diseases References for diseases
APT1 lypla1 H-Ras, RGS, Gs [94,95,99]
eNOS [96]
SNAP-23 [97]
G protein of VSV, HEF and HA
proteins of inﬂuenza virus, E2
glycoprotein of SFV
[98]
G13 [101]
CD95 [103]
APT2 lypla2 H-Ras, N-Ras [105]
GAP-43 [106]
CD95 [103]
PPT1 cln1 H-Ras, G [110] Infantile neuronal ceroid lipofuscinosis [113]
[121]
[123]
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toylated SV proteins such as vesicle-associated membrane protein 2
(VAMP2) and SNAP-25 and disturbed the maintenance of SV pools,
plausibly contributing to the abnormal neurotransmission and ulti-VAMP-2, SNAP-25 
CSP 
ynamic control of palmitoylation of substrate proteins (Fig. 1).
ased on current knowledge, depalmitoylating enzymes include
wo acyl protein thioesterases (APTs), APT1 and APT2, and the
almitoyl protein thioesterase 1 (PPT1) (Table 4).
.1. Acyl protein thioesterase 1 (APT1)
APT1, encoded by lypla1 gene, belongs to members of the
/-hydrolase family of serine hydrolases as revealed by crystal
tructure, which contain the catalytic triad Ser − His − Asp, a typi-
al feature of /-hydrolases [89–92]. APT1 was  originally puriﬁed
rom rat liver as a lysophospholipase [89,93] and later characterized
s a thioesterase in yeast [94]. APT1 has been shown to depalmi-
oylate Gs, regulator of G protein signaling (RGS) protein, H-RAS
95], eNOS [96] and SNAP-23 in vitro [97]. It has also been shown to
eacylate the G protein of vesicular stomatitis virus (VSV), HEF and
emagglutinin proteins of inﬂuenza virus, and the E2 glycoprotein
f Semliki Forest virus (SFV) in vitro [98]. Unlike the E2, E1 gly-
oprotein of SFV was not deacylated by APT1 [98], demonstrating
he substrate speciﬁcity of APT1. Palmostatin B, a small molecule
nhibitor of APT1 [99] has been shown to interrupt palmitoyla-
ion and depalmitoylation cycle at the level of depalmitoylation
nd thus to disturb the steady-state localization of Ras, identify-
ng APT1 as a thioesterase [99,100]. In hippocampal neurons, APT1
as been shown to be expressed in neuronal dendrites at the level
f mRNA and to regulate dendritic spine size [101,102]. Knock-
own of APT1 by shRNAs or enzymatic activity inhibitors of APT1,
D196 and FD253 decreased dendritic spine volume. MicroRNA-
38 (miR-138) downregulated APT1 expression [101,103], which
ed to the shrinkage in spine volume presumably through the
nhanced palmitoylation level of G13 caused by inhibited G13
epalmitoylation.
APT2, encoded by lypla2 gene, was identiﬁed from mouse
mbryo as a new lysophospholipase named lysophospholipase II,
nd displayed 64% amino acid sequence identity with APT1. Similar
o APT1, APT2 was predicted to contain the Ser − His − Asp catalytic
riad [104]. A PT2 has also been reported to depalmitoylate H-Ras
ike APT1. However, it has more efﬁcient catalytic activity than
PT1 in depalmitoylating a biologically active semisynthetic N-Ras
n vitro [105]. Overexpression of APT2, but not APT1, causes rapid
epalmitoylation of the GAP-43 [106], demonstrating the substrate
peciﬁcity of APT2. A recent report has shown that APTs regulate
he apoptosis mediated by the cluster of differentiation 95 (CD95) in
rimary chronic lymphocytic leukemia (CLL) cells [103]. APT1 and
PT2 were shown to promote depalmitoylation of CD95 through
 direct interaction with CD95 and thus to impair CD95-mediatedAdult neuronal ceroid lipofuscinosis [123]
apoptosis. This impairment was reverted by a speciﬁc downregu-
lation of APTs by siRNAs, miR-138, miR-424 or palmostatin B [103].
Unlike palmitoylation, depalmitoylation has been considered to
occur everywhere in the cell and to lack any consensus sequence or
substrate speciﬁcity [38]. However, a few studies have reported the
substrate speciﬁcity of APTs such as APT1-speciﬁc deacylation of E2
glycoprotein of SFV [98] and APT2-speciﬁc deacylation of GAP-43
[106]. It remains, however, to be solved how APTs can efﬁciently
access their substrates. APTs, including both APT1 and APT2 were
identiﬁed to be palmitoylated [107,108]. Thus, it is be plausible that
palmitoylation of cytoplasmic APTs may  facilitate to be localized to
the membrane and to interact with their substrates.
4.2. Palmitoyl protein thioesterase 1 (PPT1)
PPT1, encoded by cln1 gene, is also a member of the
/-hydrolase family harboring the classical catalytic triad,
Ser − His − Asp [109]. It was characterized as a thioesterase through
the observations that PPT1 catalyzes depalmitoylation of H-Ras
and G in vitro [110,111]. PPT1 itself, like APT1 and APT2, is also
palmitoylated at C6 by DHHC3 and DHHC7. In addition, regula-
tion of the PPT1 enzymatic activity depended on its palmitoylation
[112]. Interestingly, defects in the PPT1 gene were identiﬁed in the
infantile type of neuronal ceroid lipofuscinosis (NCL, also known
as Batten disease), a severe brain disease in childhood, which is
characterized by early loss of vision and a massive loss of cortical
neurons [113]. Although PPT1 was  interestingly found to be tar-
geted to lysosomes [114–116], PPT1 mutant (R122W), the most
common infantile NCL mutation was not targeted to the lysosomes,
but it was rather retained in the ER and remained enzymatically
inactive [113,114], suggesting PPT1 as being involved in a lysoso-
mal  enzyme deﬁciency, infantile NCL. As expected from the fact
that PPT1 gene is linked to the infantile NCL which is a neu-
rodegenerative disorder, PPT1 has been implicated to play roles
in the neuronal functions. PPT1 is widely expressed in the brain,
localizes synaptosomes and synaptic vesicles (SVs), and colocalizes
with presynaptic proteins, synaptophysin or GAP-43 [117–121].
PPT1 deﬁciency caused persistent membrane retention of palmi-mately to infantile NCL pathology [121]. PPT1 mutant mice lacking
the exon 4 exhibited a prominent loss of GABAergic interneurons in
the brain [122]. A recent study reported that CSP is depalmitoylated
by PPT1 and hence a substrate for PPT1 [123].
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.3. Other palmitoyl thioesterases: PPT2 and APTL1
PPT2 was isolated as a second lysosomal hydrolase which was
hown to share an 18% homology at the level of amino acid with
PT1 and to possess palmitoyl-CoA thioesterase activities compa-
able with PPT1 [124]. However, PPT2 did not depalmitoylate the
-Ras [124], which was depalmitoylated by PPT1 in the past study
110], suggesting the substrate speciﬁcity and differential functions
f PPT2 distinct from PPT1. Indeed, knockout mice studies have pro-
ided the evidence that PPT2 could serve a distinct role in the brain
part from PPT1 [125]. PPT2 knockout mice showed the milder NCL
henotypes such as reduced clasping behavior, enhanced survival
ate, and lesser autoﬂuorescent storage material compared to the
PT1 knockout phenotypes. Smaller lipid binding pocket of PPT2
han that of PPT1 revealed by crystal structure [126] could further
upport the distinct role of PPT2 and may  explain the preference of
PT2 thioesterase activity for palmitoyl-CoA over the palmitoylated
roteins [124].
APTL1, encoded by lyplal1 gene, is a homologue of APT1 with
1% identity at the amino acid sequence level. APTL1 also con-
ains the catalytic triad conserved [127]. Unlike APT1 but similar
o PPT2, APTL1 features a narrow substrate-binding pocket which
refers short-chain substrates, thus showing a limited function as
 palmitoyl thioesterase [128]. Currently, there is no report on the
protein” substrates for PPT2 and APTL1 with the possibilities that
hey may  not serve as thioesterases for the palmitoylated proteins
r the protein substrates for PPT2 and APTL1 may  exist but have
et to be identiﬁed. Given that there are at least 23 DHHC PATs
ith speciﬁc substrates, it is well worth paying continuous effort
o identify more potential thioesterases and test whether they play
 role as thioesterases.
. Palmitoylation in Alzheimer’s disease
Protein palmitoylation is an important process to regulate phys-
ological function of the brain. Indeed, numerous studies have
eported that defects in palmitoylation step or in the enzymes for
almitoylation and depalmitoylation are associated with several
eurological disorders such as AD, HD, schizophrenia, ID, and NCL.
n this section, we will review the work providing evidence for the
nvolvement of palmitoylation in several neurological disorders, in
articular with more intensive focus on the AD.
.1. Amyloidogenic and non-amyloidogenic process of amyloid
recursor protein
Alzheimer’s disease (AD) is the most common form of neu-
odegenerative disorders characterized by neuronal dysfunctions
hat lead to a cognitive decline and progressive memory loss. The
ost well-known neuropathological feature of AD is the formation
f amyloid plaques [129] by neurotoxic extracellular -amyloid
A) aggregation in the brain [130–133]. A is a 38 − 43 amino
cid fragment derived from the sequential proteolytic process-
ng of amyloid precursor protein (APP) by -secretase (-site
PP cleaving enzyme 1, BACE1) and -secretase [132,134]. APP
n non-amyloidogenic pathway is primarily cleaved by the -
ecretase whereas APP in amyloidogenic pathway is internalized
nd cleaved by the -secretase/BACE1 on endosomes and then by
he -secretase complex to generate A. Although most A pep-
ides are secreted to extracellular space, some A peptides may
ggregate in late endosomes or lysosomes contributing to intra-
ellular A accumulation [135,136]. A recent work has suggested
 differential role of intracellular A presumably depending on
he degree of intracellular A accumulation by examining a rapid
ynaptic delivery of GluA1 in response to intracellularly applied Aesearch 111 (2016) 133–151
[137]. Genetic mutations responsible for early-onset familial AD
(FAD) are isolated in APP and presenilin, an essential component of
-secretase complex [138].
5.2. Palmitoylation and A  ˇ production
Co-immunoprecipitation assay revealed that DHHC12 is
an alcadein and APP interacting DHHC protein (AID) [139].
DHHC12/AID suppressed APP trafﬁcking by tethering APP in the
Golgi, which attenuated its further trafﬁcking to the trans-Golgi
network (TGN) and the plasma membrane and inhibited APP
metabolism, including A generation, which was dependent on
the DHHC motif of DHHC12/AID (Fig. 3). A mutant DHHC12/AID
of which palmitoyl transferase activity was impaired by replac-
ing the DHHC with the Ala-Ala-His-Ser (AAHS) still showed the
suppressed APP trafﬁcking and metabolism but signiﬁcantly facil-
itated -cleavage of APP through the activation of a disintegrin
and metalloproteinase 17 (ADAM17) [139], a major -secretase
[140,141] indicating that amyloidogenic pathway producing A
was DHHC12/AID-mediated palmitoylation independent while
non-amyloidogenic -cleavage of APP was DHHC12/AID-mediated
palmitoylation dependent. A recent study provided more direct
evidence on the involvement of palmitoylation in the AD pathogen-
esis by showing that APP is palmitoylated in vitro and in vivo and
APP palmitoylation regulates amyloidogenic process [142] (Fig. 3).
It was  found that APP is palmitoylated at C186 and C187 in N-
terminal region structured toward the extracellular area. APP was
not palmitoylated in the APP mutants with the cysteine residues
at C186 and C187 replaced with serines such as APP-C186S, APP-
C187S, and APP-C186,187S, and such palmitoylation-deﬁcient APP
mutants were retained in the ER (Fig. 3). DHHC7 and DHHC21
were shown to palmitoylate APP and overexpression of DHHC7 and
DHHC21 increased A production as well as APP palmitoylation.
Palmitoylated APP enriched in lipid rafts was  shown as a better sub-
strate for BACE1 than -secretase and the palmitoylation increased
the BACE1-mediated cleavage of APP in lipid rafts [142], indicating
that APP palmitoylation enhances amyloidogenic pathway produc-
ing A (Fig. 3). Therefore, some strategies targeting the prevention
of APP palmitoylation by developing speciﬁc inhibitors might need
to be adopted to prevent and/or treat AD.
Palmitoylation of an APP interacting protein SCG10/stathmin
2 [143] which is a member of stathmin family and speciﬁcally
expressed in neurons [144] was  shown to be important in the
APP processing [143]. SCG10/stathmin 2 was palmitoylated at C22
and C24 in N-terminal region [145,146], and SCG10/stathmin 2
palmitoylation mediated by Golgi-resident DHHC3/GODZ, DHHC7,
and DHHC15 [147] contributed to its membrane association and
APP processing [143]. SCG10/stathmin 2 was shown to directly
interact with the KFFEQ motif of the APP intracellular domain
(AICD) [143]. Overexpression of SCG10/stathmin 2 increased sAPP
and decreased A1–40 in cultured mouse cortical neurons over-
expressing APP, indicating that SCG10/stathmin 2 promotes the
non-amyloidogenic processing of the APP (Fig. 3). Consistently,
SCG10/stathmin 2 overexpression reduced A accumulation and
amyloid plaque formation in the hippocampus of APPSwe/PS1E9
mice [143], an AD model harboring APP Swedish mutations
(APPSwe) and exon 9 deletion (E9) of the presenilin 1 [148].
Knockdown of SCG10/stathmin 2 decreased -secretase cleavage
products, sAPP and C-terminal fragment  (CTF), and it increased
A1–40 and A1–42. Overexpression of palmitoylation-deﬁcient
SCG10/stathmin 2 mutant decreased the level of A1−40 and A1−42
in a signiﬁcantly lesser degree compared to SCG10/stathmin 2-
WT,  indicating that palmitoylation of SCG10/stathmin 2 affects
the APP processing. Therefore, these results suggest that iden-
tifying a PAT for SCG10/stathmin 2 would be the next step to
investigate and developing methods blocking the palmitoylation of
E. Cho, M.  Park / Pharmacological Research 111 (2016) 133–151 141
CTF α
sAPPα
ER
Golgi
sAPP β
Aβ
Amyloid
plaq ues
DHHC12
alcadein
TGN
SCG10  
DHHC3, 
DHHC7, 
DHHC15  
C186,187 S 
mutant APP
PM
CTFβ
sAPP β
BACE1DHHC3, 
DHHC4, DHHC7, 
DHHC15 , DHHC20  
flotillin-1
lipid 
raft s
APP
flotillin-2
DHHC5
Aβ
γ-sec retase
complex
nicas trin
PEN2 lipid raft s
DHHC7, 
DHHC21
Non-amyloidogenic process Amyloidogenic process
Fig. 3. Palmitoylation of AD-related proteins and the role of palmitoylation in AD pathogenesis.
In  the non-amyloidogenic process, an alcadein and APP interacting DHHC protein DHHC12/AID suppresses APP trafﬁcking in the Golgi and further to the late secretary pathway
and  also inhibits APP metabolism, including A generation. DHHC12/AID negatively regulates the -secretase activity in non-amyloidogenic process. SCG10/stathmin 2 is
palmitoylated at C22 and C24 in N-terminal region by Golgi-resident DHHC3/GODZ, DHHC7 and DHHC15, interacts with AICD, and promotes APP trafﬁcking from Golgi to the
plasma  membrane, affecting non-amyloidogenic processing of APP in a palmitoylation-dependent manner. In the amyloidogenic process, APP is palmitoylated at C186 and
C187  in N-terminal region toward the extracellular area, and the palmitoylation of APP enhances amyloidogenic pathway producing A. DHHC7 and DHHC21 increased APP
palmitoylation and A production as well. Palmitoylation-deﬁcient APP mutants (APP-C186S, APP-C187S, and APP-C186,187S) are retained in the ER whereas palmitoylated
APP  is enriched in lipid rafts, resulting in upregulation of APP cleavage by BACE1. BACE1 is palmitoylated at C478, C482, and C485 within the C-terminal cytosolic region and
at  C474 within the transmembrane domain. DHHC3/GODZ, DHHC4, DHHC7, DHHC15, and DHHC20 promote palmitoylation of BACE1, which may  facilitate the amyloidogenic
processing of APP by targeting BACE1 to lipid rafts. Palmitoylation-mediated subcellular localization of BACE and the contribution of BACE1 palmitoylation to the AD are still
unclear. Flotillins/reggies are palmitoylated at C34. Palmitoylation of ﬂotillin-2/reggie-1 can be regulated by DHHC5. Flotillin-1/reggie-2 directly binds to the cytoplasmic
t  BACE
n  nicas
m
S
f
5
a
t
t
D
l
t
c
t
g
w
eail  of BACE1 and both ﬂotillins are putative regulators for the trafﬁcking of APP and
icastrin and APH-1 were reported to be palmitoylated, and the palmitoylation of
odulation of A deposition in the brain.
CG10/stathmin 2 could be useful source for the therapeutic target
or AD.
.3. BACE1 palmitoylation and APP processing
BACE1, an aspartyl protease containing a long extracellular cat-
lytic domain and a single TMD  [149] has also been reported
o be palmitoylated at C478, C482, and C485 within the C-
erminal cytosolic region [150] and at C474 within the TMD  [151].
HHC3/GODZ, DHHC4, DHHC7, DHHC15 and DHHC20 were iso-
ated as PATs for BACE1 and signiﬁcant amount of BACE1 was
argeted to lipid rafts in a palmitoylation-dependent manner [151].
The role of palmitoylation of BACE1 in A production has been
ontradictory to date. Non-palmitoylated form of BACE1 lacking
he TMD  and cytoplasmic tail was reported to enhance amyloido-
enic processing of APP, leading to A production unlike BACE1
ildtype [150]. In contrast, when the BACE1 was engineered to be
xclusively located to lipid rafts by adding glycosylphosphatidyli-1, with being implicated in AD pathology. Among subunits of -secretase complex,
trin and APH-1 plays a role in the protein stability, their raft localization, and the
nositol (GPI) anchor to the ectodomain of BACE1 (BACE1-GPI),
both sAPP secretion and A production were upregulated [152].
Given that BACE1 is located to lipid rafts depending on its palmi-
toylation, BACE1 palmitoylation would promote A production.
Indeed, palmitoyltransferase inhibitor cerulenin decreased A pro-
duction, supporting the idea that palmitoylation of BACE1 would
be required for A production [153,154]. While these controver-
sial ﬁndings on the role of BACE1 palmitoylation in A production
were reported, two  surprising reports were made on no inﬂuence of
BACE1 palmitoylation on A production [151,155]. Palmitoylation-
deﬁcient BACE1 whose 4 cysteines (C474, C478, C482, and C485)
were substituted by alanine residues (BACE1-CA4) exhibited non-
raft localization and did not affected the BACE1 processing of APP
or secretion of A, indicating that palmitoylation of BACE1 is not
required for APP processing and also even lipid rafts localization of
BACE1 is not important for its cleavage activity of APP [151,155].
So far, the contribution of BACE1 palmitoylation to A production
and AD is still unclear, and it needs further investigation.
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.4. -Secretase complex palmitoylation and APP processing
-Secretase acts on CTF (CTF99) to generate the AICD and
he A subsequent to BACE1. The -secretase is a multiprotein
omplex, consisting of at least four catalytic subunits [156], pre-
enilins [156,157], the presenilin enhancer 2 (PEN2) [158], the
nterior pharynx-defective 1 (APH-1) [159], and nicastrin [160]
Fig. 3). Although presenilins, PEN2, APH-1, and nicastrin have been
nown to be sufﬁcient for -secretase processing of APP, a report
dentiﬁed a type I transmembrane protein p23 as a component
f -secretase that modulates -secretase activity and regulates
ecretory trafﬁcking of APP [161,162]. Nicastrin and APH-1 were
eported to be palmitoylated at transmembrane C689 in nicastrin
nd at cytosolic C182 and C245 in APH-1 [163]. Co-overexpression
f palmitoylation-deﬁcient nicastrin and APH-1 caused a protein
nstability and reduced their lipid raft association whereas the
almitoylation deﬁciency of nicastrin and APH-1 did not inﬂu-
nce A40, A42, CTF, P3, CTF and AICD production, suggesting
hat palmitoylation of nicastrin and APH-1 plays a role in the
rotein stability and raft localization but not in -secretase activ-
ty and amyloidogenic and non-amylodogenic processing of APP
163]. The same group generated transgenic mice co-expressing
almitoylation-deﬁcient APH1aL and nicastrin in the forebrain and
ound that palmitoylation deﬁciency did not affect the ability of
PH1aL, an isoform of APH-1 and nicastrin to form enzymatically
ctive -secretase complexes [164]. However, interestingly, the
ransgenic mice co-expressing palmitoylation-deﬁcient APH1aL
nd nicastrin exhibited a signiﬁcant but moderate reduction of
myloid deposits in the forebrain and a lower level of insoluble
, indicating a potential role of -secretase palmitoylation in the
odulation of A deposition in the brain.
.5. Fyn and ﬂotillins/reggies palmitoylation and AD pathology
Many studies have suggested that Fyn and ﬂotillins/reggies are
mplicated in AD pathology and their palmitoylation has also been
mplicated to serve a role in AD. In addition to the formation
f amyloid plaques by A aggregation, another neuropatholog-
cal feature of AD is intracellular neuroﬁbrillary tangles (NFTs)
hich are mainly composed of hyper-phosphorylated tau whose
hosphorylation is caused by Fyn kinase [165–168]. Tau protein,
ne of microtubule-associated protein (MAP) family together with
AP2, MAP4 and others, is involved in regulation of microtubule
ytoskeleton stabilization [169]. In the basal state, tau protein inter-
cts with tubulin and promotes tubulin assembly into microtubules
Fig. 4A), which contribute to the normal morphology and struc-
ural support for neuronal cells [170]. Tubulin binding of tau is
egulated by its phosphorylation state through coordinated action
f kinases and phosphatases [171]. In AD, tau is not only abnormally
yper-phosphorylated and loses its tubulin binding capacity, lead-
ng to microtubule disorganization, but it is also self-polymerized,
elf-assembled and aggregated, resulting in the formation of the
aired helical ﬁlaments (PHFs) and NFTs [172] (Fig. 4A). Tau is phos-
horylated by Fyn kinase at Tyr18 (Y18), one of phosphorylation
ites among 5 tyrosine residues of tau protein, and phosphorylated
au at Y18 was found in NFTs in human AD brain, suggesting a pos-
ible clinical relationship between tau phosphorylation at Y18 and
D [165,167,168] (Fig. 4B). Tau was reported to directly interact
ith Fyn via Fyn SH2 domains [173] or Fyn SH3 domains [165,168].
yn expression was reported to be elevated in AD brain [174], and
t was also shown that up-regulation of Fyn affected A-dependent
ynaptic and cognitive impairments, neuronal death, and prema-
ure mortality in APP transgenic mice, whereas down-regulation
f Fyn protected against A toxicity [175–177]. Therefore, Fyn has
een suggested to play a role in A-tau-dependent neuronal dys-
unction in AD [178,179]. Fyn was revealed to be palmitoylatedesearch 111 (2016) 133–151
[180] at C3 and C6 in SH4 domain [181,182], and DHHC21 was
identiﬁed as a PAT for Fyn [34]. Palmitoylation-deﬁcient Fyn whose
cysteine residues at C3 and C6 were replaced with serines (Fyn-
C3S/C6S) was failed to localize to the plasma membrane in HEK293
cells and to the dendritic spines in cultured primary neurons but
Fyn-C3,6S was accumulated on intracellular compartments, endo-
somes [181,182] (Fig. 4B), indicating that palmitoylation of Fyn
is required for a proper subcellular localization and thus proper
function of Fyn [181,182]. Therefore, it can be suggested that the
palmitoylation of Fyn may  inﬂuence the A-Tau-Fyn toxic trade.
By adopting the view of synaptic tau in AD [183], given that LTD-
inducing NMDA receptor stimulation led to tau phosphorylation,
which regulates the interaction with Fyn [184], and that tau phos-
phorylation is required for LTD [184,185], which could be a cellular
basis for aberrant synaptic weakening and loss observed in AD
[183], and that palmitoylation of the protein interacting with C-
kinase (PICK1), a GluA2-interacting protein [186] is critical for
cerebellar LTD induction [187], investigating palmitoylation of tau-
and/or glutamate receptor-regulating factors will provide insights
into synaptic roles of palmitoylation particularly in AD.
Flotillins/Reggies, originally identiﬁed as neuronal proteins
upregulated during the axon regeneration after injury of the optic
nerve [188,189] has also been implicated in AD pathology. Flotill-
ins/Reggies were accumulated in AD brains [190,191] and the level
of increased ﬂotillins/reggies depended on the enhancement of
A deposition [192]. Many studies have suggested the putative
roles of ﬂotillins/reggies in AD as regulators for the trafﬁcking of
APP and BACE1, inﬂuencing the amyloidogenic processing of APP
[193–197]. Interestingly, ﬂotillins/reggies are palmitoylated; both
ﬂotillin-1/reggie-2 and ﬂotillin-2/reggie-1 are palmitoylated at a
conserved cysteine residue C34, while ﬂotillin-2/reggie-1 is also
myristoylated [198,199]. Palmitoylation of ﬂotillin-2/reggie-1 was
mediated by DHHC5 [84]. Palmitoylation of ﬂotillins/reggies was
revealed as a crucial process for the membrane association of ﬂotill-
ins/reggies. Although there have been no report showing a direct
link between ﬂotillin/reggie palmitoylation and AD, considering
their putative roles in AD, it would be worthwhile to investigate
a role of ﬂotillin/reggie palmitoylation in AD pathogenesis.
5.6. Possible role of Apolipoprotein E palmitoylation on the
late-onset sporadic AD?
Only less than 3% of AD cases account for FAD carrying the
genetic mutations. Currently, most of the AD patients suffer from
the late-onset sporadic AD (LOAD) which may not involve genetic
mutations for A production, implying that an increase in A gen-
eration by genetic background is probably not the major pathogenic
mechanism underlying LOAD [200,201], but rather a defect in A
clearance for blocking an increase or accumulation of toxic A could
underlie AD pathogenesis in LOAD [132,202,203]. Apolipoprotein
E (apoE), the major apolipoprotein in the central nervous system
(CNS), is one of the well-studied factors for the LOAD pathogen-
esis especially in the process of A clearance and aggregation.
Numerous studies have demonstrated the differential effect of apoE
isoforms on amyloidogenesis, including the production, aggrega-
tion, and clearance of A  ˇ in vivo and in vitro [204,205]. It was
reported that apoE is produced in selected classes of neurons under
certain conditions, such as aging and brain injury [206–209] and
plays a role in synaptogenesis, maintenance of synaptic connec-
tions [210], neurite outgrowth in an isoform-dependent manner
in vitro, synaptic plasticity and cognitive function, including learn-
ing and memory in vivo [211,212]. Therefore, it is suggested that
apoE is involved in synaptic dysfunction of AD even though apoE-
mediated cellular mechanisms underlying AD pathogenesis are
standing to be uncovered.
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Fig. 4. Structure and pathology of tau protein and palmitoylation-related function of Fyn kinase.
In  healthy neurons, tau proteins interact with tubulin, contributing to microtubule stability for supporting normal morphology and structure of cells. Phosphorylation of
tau  is a regulatory factor for microtubule stability. In diseased neurons, abnormal hyper-phosphorylation of tau leads to microtubule collapse and insoluble cytoplasmic tau
aggregation. Aggregated and hyper-phosphorylated tau proteins twist to form paired helical ﬁlaments (PHFs), which assemble to produce neuroﬁbrillary tangles (NFTs), a
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inase  is palmitoylated by DHHC21. Palmitoylation-deﬁcient Fyn (Fyn-C3,6S) is ac
ubcellular localization and thus involved in localization and phosphorylation of ta
ApoE has three major isoforms, apoE2, apoE3 and apoE4. They
ave been considered to play differential roles in LOAD. ApoE3 is
he most predominant isoform, accounting for almost 77% of the
on-AD general population, while apoE2 is the most minor iso-
orm found in 8% and apoE4 found up to 15% of the non-AD general
opulation. However, apoE4 is more frequently found over 40%
n AD patients [213], and this rate even goes up to 65% to 80% in
OAD patients. Therefore, it is likely suggested that apoE4 would
e a major risk factor for LOAD [205,213–217] while the most
inor isoform apoE2 exhibited a protective effect against LOAD205,213,216,217]. Interestingly, these three isoforms of apoE pro-
eins are only different in one or two amino acids at 112th and/or
58th residues; apoE2 has two cysteine residues, C112 and C158,
poE3 has two different residues, C112 and R158, and apoE4 hasorylates tau at Tyr18 (Y18) and facilitates trafﬁcking of tau to dendritic spines. Fyn
lated on endosomes in cultured neurons. Palmitoylation of Fyn is required for its
ein.
two arginines, R112 and R158. These differences can alter their
folding structure and ability to bind with lipid and their receptors
[218,219].
So far, there has been no report on whether apoE proteins are
palmitoylated. Intriguingly, it is highly plausible that apoE2 and
apoE3 might be palmitoylated at both C112 and C158 and only at
C112, respectively. In silico screening of apoE palmitoylation using
CSS palm ver.4.0 program [69] reveals that C112 and C158 of apoE2
and C112 of apoE3 were predicted to be palmitoylated with high
scores whereas apoE4 was predicted to have no putative site for
palmitoylation (unpublished data in the Park laboratory). Given that
apoE4 was suggested to be a risk factor while apoE2 being sug-
gested to serve a protective role for LOAD and also that apoE4 was
predicted not to be palmitoylated but apoE2 was predicted to be
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almitoylated, it can be hypothesized that apoE2 palmitoylation at
112 and C158 might contribute to the protective role acting on
he A clearance process in LOAD. Manipulating ApoE2 palmitoy-
ation would be considered as a way for therapeutic development
n LOAD. It is currently still inconclusive whether palmitoylation
f speciﬁc proteins alters AD pathogenesis. There is, however, no
oubt in the need for further studies to clarify the speciﬁc role of
almitoylation in AD.
. Palmitoylation in other neurodegenerative diseases
.1. Huntington’s disease
Huntington disease (HD) is a neurodegenerative disease char-
cterized by cognitive decline, motor dysfunction, and psychiatric
isturbance [220,221]. HD is caused by a mutation in the huntingtin
ene by an expansion of CAG trinucleotide repeat to greater than
5 repeats, resulting in an abnormal huntingtin protein with a long
olyglutamine, poly(Q) tail in its N-terminal region [29]. Loss of
edium spiny neurons (MSNs) and loss of the striatal volume are
bserved as key pathological features of HD [222]. Huntingtin was
hown to be highly expressed in neurons [223], and DHHC17/HIP14
hat is a PAT for huntingtin was originally isolated as a huntingtin-
nteracting protein by Y2 H screening [40]. Its interaction with
untingtin is inversely correlated with the poly(Q) length of hunt-
ngtin, suggesting that reduced interaction of DHHC17/HIP14 with
untingtin could contribute to the pathogenesis of HD. Moreover,
HHC17/HIP14 is abundantly and widely expressed in the brain,
articularly in striatal MSNs whose cell loss is a neuropathological
haracteristic of HD [40].
.1.1. Huntingtin and palmitoylation
Huntingtin was reported to be palmitoylated at C214, and a
utation of huntingtin at this Cys replaced with Ser (C214S)
ncreased NMDA-induced neuronal toxicity and inclusion forma-
ion [224]. Knockdown of DHHC17/HIP14 in cortical neuronal
ultures from the YAC128 transgenic mouse model of HD, which
as a full-length human huntingtin transgene with 128 CAG repeats
225], increased the inclusion formation of huntingtin whereas
verexpression of DHHC17/HIP14 signiﬁcantly reduced the hunt-
ngtin accumulation in the inclusion [224]. Palmitoylation level
f huntingtin was signiﬁcantly diminished in brain extracts of
AC128 mice, which could be explained by reduced palmitoy-
ation activity of DHHC17/HIP14 most likely due to a weakened
nteraction between mutant huntingtin and DHHC17/HIP14 [224].
hese suggest an important role for palmitoylation in HD. YAC128
ice exhibited brain weight reduction and striatal volume loss,
ncluding MSNs loss with motor and cognitive dysfunctions [225].
imilar to YAC128 mice, DHHC17/HIP14 null mice, hip14 / , dis-
layed a reduced striatal volume and behavioral deﬁcits like
D [226]. DHHC17/HIP14 protein levels were not changed but
HHC17/HIP14 was dysfunctional in the presence of mutant hunt-
ngtin in YAC128 mice, suggesting that altered palmitoylation of
untingtin mediated by DHHC17/HIP14 may  contribute to HD
226]. In addition, hip14 / mice exhibited a decrease in excita-
ory synapses in striatum [226] and in hippocampus [227]. Hip14 /
ice also resulted in impaired hippocampal LTP and spatial mem-
ry [227], suggesting that loss of DHHC17/HIP14 may  account for
he cognitive symptoms in HD.
Huntingtin is also a substrate for DHHC13/HIP14-like
HIP14L) [76,228], which was identiﬁed by database searches
or DHHC17/HIP14 homologs [40] DHHC13/HIP14L is the only
AT having a DQHC motif instead of the canonical DHHC motif
25,29,52]. While DHHC17/HIP14 has a number of substrates for
almitoylation, the speciﬁc substrates of DHHC13/HIP14L areesearch 111 (2016) 133–151
still limited. DHHC13/HIP14L was only reported to palmitoylate
GAD65 [76], huntingtin [76,229], and SNAP-25 [230]. It was
recently reported that the DHHC13/HIP14L-deﬁcient hip14l /
mice exhibited the HD-like progressive neuropathological deﬁcits,
including progressive loss of striatal and cortical volume and
motor impairment [230]. Palmitoylation levels of neuronal sub-
strate SNAP-25, but not PSD-95 were diminished in hip14l / mice.
In addition, DHHC13/HIP14L interaction with mutant huntingtin
was reduced compared to wildtype huntingtin [230]. These ﬁnd-
ings suggest that reduced palmitoylation of neuronal substrate in
hip14l / mice may  contribute to the pathogenesis of HD. Taken
together, dysfunction of DHHC17/HIP14 and DHHC13/HIP14L is
implicated in HD.
DHHC17/HIP14 was reported to bind with the N-terminal region
of huntingtin through its ankyrin domain, and the binding regions
were mapped to amino acids 1–548 of huntingtin and amino acids
89–257 of DHHC17/HIP14 [76,228]. A recent study identiﬁed two
potential binding domains around amino acids 224 and 427 of
huntingtin for both DHHC17/HIP14 and DHHC13/HIP14 L [231].
Since huntingtin affects the palmitoylation of DHHC17/HIP14 and
DHHC13/HIP14L substrates by modulating the PAT enzymatic
activity [228], a further characterization on the interactions of
huntingtin with DHHC17/HIP14 and/or DHHC13/HIP14L would
extend the current understandings on the mechanisms underlying
HD pathogenesis.
The Y2H study of DHHC17/HIP14, which is the ﬁrst comprehen-
sive work to discover interacting partners of a mammalian PAT,
found that there are signiﬁcant overlap between DHHC17/HIP14
interacting partners screened by Y2H and huntingtin interacting
partners that are previously reported [232]. Interestingly, about
half of the 36 overlapped binding partners have already been
reported to be implicated in HD, providing a support for a direct
link between DHHC17/HIP14 and HD. In addition, the neuronal
membrane glycoprotein M6A  (GPM6A) and the Sprouty domain-
containing proteins SPRED1 and SPRED3 were identiﬁed as novel
substrates of DHHC17/HIP14 from palmitoylated proteins among
DHHC17/HIP14 Y2H binding partners, supporting that altered
palmitoylation by DHHC17/HIP14 could be an important mecha-
nism contributing to the HD pathogenesis. Further investigations
on functional interactions between huntingtin and DHHC17/HIP14
or DHHC13/HIP14Lwill provide fruitful clues to understand HD
pathophysiology.
6.2. Schizophrenia
Schizophrenia is a psychiatric disorder often characterized
by abnormal social behavior and pervasive cognitive deﬁcits.
Decreased palmitoylation of many proteins were reported to be
found in the dorsolateral prefrontal cortex from schizophrenia
patients [233]. Among palmitoylating enzymes, DHHC8 has been
demonstrated as a key PAT/DHHC associated with schizophrenia.
The dhhc8 gene located in the microdeletion region of chromosome
22q11 was reported to be associated with a risk of schizophre-
nia [234,235]. In particular, polymorphisms in the dhhc8 gene
have been reported for its association with a risk of schizophre-
nia [36,236] but those associations seemed to be dependent on
ethnic groups, making the associations of the dhhc8 polymor-
phisms and schizophrenia still controversial. There were reports
showing signiﬁcant association between 3 single-nucleotide poly-
morphisms (SNPs) in dhhc8 gene and schizophrenia in the U.S. and
South African populations [237] and in the Han Chinese popula-
tion as well [238]. One of these 3 SNPs, rs175174 located in intron
4 of dhhc8 gene, was  also identiﬁed to be strongly and function-
ally associated with schizophrenia in American and South African
patients, particularly in female patients [36]. The SNP rs175174
modulated the retention of intron 4 of dhhc8,  which introduces
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 premature stop codon in vitro, thereby inﬂuencing an alterna-
ive splicing of dhhc8 and putatively leading to a truncated inactive
orm of DHHC8. Moreover, dhhc8 knockout mice exhibited sexually
imorphic deﬁcits in prepulse inhibition and reduction in loco-
otor activity in an open ﬁeld test of spontaneous exploratory
ehavior under mildly stressful conditions, which is more severe
n female than male mice [36]. A subsequent study demonstrated
hat dhhc8-deﬁcient mice showed a decrease in dendritic spine
ensity [239] and disruption of axonal growth [240]. In contrast to
he studies described above, several studies have demonstrated no
ssociation between dhhc8 gene and susceptibility to schizophre-
ia [236,241–246]. Some reports have demonstrated that there was
o association between the SNP rs175174 and schizophrenia in a
arge European samples [241] and the Japanese population as well
242,243]. A recent study using meta-analytic techniques failed to
nd an association between the dhhc8 gene locus and susceptibility
o schizophrenia [246]. However, another report that did not ﬁnd
n association between dhhc8 polymorphisms and schizophrenia
n Korean population found an association with smooth pur-
uit eye movement (SPEM) abnormality, which is a feature of
chizophrenia, suggesting that dhhc8 gene might inﬂuence differ-
nt aspects of schizophrenia [247]. An association between dhhc8
nd schizophrenia could be restricted in closely linked genetic
ocus based on speciﬁc ethnic groups or dhhc8 might be indirectly
mplicated in schizophrenia. In a 22q11.2-deletion mouse model
f schizophrenia Df(16)A+/− mice, axonal growth and branch-
ng was disrupted in vivo and these deﬁcits were rescued when
HHC8 was exogenously expressed in the mice [240]. In addition,
 schizophrenia-related circuit, a prefrontal cortex − hippocampus
onnectivity and spatial working memory were impaired in dhhc8-
eﬁcient mice. These data further support an association of DHHC8
ith schizophrenia. It will need to further dissect the molecular
echanisms underlying palmitoylation in schizophrenia.
.3. Intellectual disability
Intellectual disability (ID) is a developmental disorder with an
nset under the age of 18 and is deﬁned by signiﬁcant limitations
n cognitive and adaptive functioning such as daily living skills,
ocial skills and communication skills [248,249]. DHHC15 [250] and
HHC9 [248,251,252] have been implicated in X-linked ID (XLID).
-inactivation and gene expression studies have revealed that the
ranslocation breakpoint within the ﬁrst exon of the dhhc15 gene,
lso located on the X chromosome, disrupted the transcription of
hhc15 gene in a female patient with severe nonsyndromic XLID,
uggesting DHHC15 as a strong candidate for nonsyndromic XLID
250]. In addition, four mutations, including one frameshift, one
plice-site, and two missense mutations in dhhc9 gene at Xq26.1
ere identiﬁed in 4 out of 250 families with XLID [251]. Another
ecent study has also identiﬁed two naturally occurring variants
f dhhc9,  encoding R148 W and P150 S from XLID patients [252].
oth mutations affected the steady state autopalmitoylation level
f DHHC9 through distinct mechanisms. This altered autopalmi-
oylation level of DHHC9 is predicted to affect the palmitoylation
f target proteins that might be involved in intellectual develop-
ent [252]. By combining the value of next generation sequencing,
t would be important to identify novel target proteins of DHHC9
ssociated with ID for providing molecular diagnosis and therapeu-
ic treatment [249,253].
. PerspectivesWhile substrate speciﬁcity of PATs/DHHCs and protein
hioesterases is rather broad − some PATs/DHHCs have been
eported to have more than 10 even 20 speciﬁc substrates, veryesearch 111 (2016) 133–151 145
little work has been investigated on how the palmitoylation or
depalmitoylation of their individual substrates is individualized in
terms of mechanistic regulations. Recently, the prolyl isomerase
FK506-binding protein 12 (FKBP12) was reported to facilitate
depalmitoylation of H-Ras [254], which may individualize and
specify the regulatory mechanisms of H-Ras depalmitoylation by
suggesting that H-Ras depalmitoylation is not solely dependent
on protein thioesterases. Work on identifying and verifying more
potential thioesterases, and further detailed and speciﬁed mecha-
nisms dissecting the palmitoylation and depalmitoylation cycle of
individual substrates will improve current understanding on the
roles of palmitoylation in physiology and pathophysiology of neu-
ronal (dys)functions.
In addition to palmitoylation, other PTMs, including phospho-
rylation, ubiquitination, sumoylation and nitrosylation have been
demonstrated to inﬂuence synaptic function and pathophysiol-
ogy of neurodegenerative diseases [255–259]. Further, crosstalk
among these PTMs has also been demonstrated to contribute
to ﬁne tuning of the regulation of synaptic protein functions
[27,260,261]. Knockdown of any DHHCs palmitoylating the alter-
natively spliced stress-regulated exon (STREX) variant of the
intracellular C-terminal domain of the large conductance calcium-
and voltage-activated potassium (BK) channels prevented the pro-
tein kinase A (PKA)-mediated inhibition of STREX channels [88],
providing an evidence for an interplay between palmitoylation and
phosphorylation to regulate STREX channels. In addition, a recip-
rocal control of synaptic targeting of PSD-95 was reported to be
mediated by an interplay between palmitoylation and nitrosylation
[260]. Furthermore, sumoylation of tau was  reported to plausi-
bly affect tau aggregation by increasing its phosphorylation and
inhibiting the ubiquitination-mediated degradation of tau [261].
Given the emerging evidence on the potential crosstalk among
the PTMs in precisely controlling the cellular function of pro-
teins, which further greatly increases the functional complexity of
proteins including the speciﬁcity of individual substrates of palmi-
toylating and depalmitoylating enzymes, unraveling the complex
mechanisms involved in (de)palmitoylation-mediated control of
neuronal functions would help develop broad spectra toward
therapeutic development in respect to diagnosis, prevention or
treatment for various neurodegenerative diseases.
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